Innate Pharma (IPHA) Competitors $1.51 +0.05 (+3.42%) (As of 11:40 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IPHA vs. SLRN, KRRO, AQST, AKBA, AURA, FHTX, CGC, KALV, GHRS, and TNGXShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Acelyrin (SLRN), Korro Bio (KRRO), Aquestive Therapeutics (AQST), Akebia Therapeutics (AKBA), Aura Biosciences (AURA), Foghorn Therapeutics (FHTX), Canopy Growth (CGC), KalVista Pharmaceuticals (KALV), GH Research (GHRS), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. Acelyrin Korro Bio Aquestive Therapeutics Akebia Therapeutics Aura Biosciences Foghorn Therapeutics Canopy Growth KalVista Pharmaceuticals GH Research Tango Therapeutics Innate Pharma (NASDAQ:IPHA) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do insiders and institutionals hold more shares of IPHA or SLRN? 0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 87.3% of Acelyrin shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by company insiders. Comparatively, 13.6% of Acelyrin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, IPHA or SLRN? Innate Pharma has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Does the MarketBeat Community favor IPHA or SLRN? Innate Pharma received 28 more outperform votes than Acelyrin when rated by MarketBeat users. However, 60.00% of users gave Acelyrin an outperform vote while only 57.33% of users gave Innate Pharma an outperform vote. CompanyUnderperformOutperformInnate PharmaOutperform Votes4357.33% Underperform Votes3242.67% AcelyrinOutperform Votes1560.00% Underperform Votes1040.00% Does the media prefer IPHA or SLRN? In the previous week, Acelyrin had 3 more articles in the media than Innate Pharma. MarketBeat recorded 5 mentions for Acelyrin and 2 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.87 beat Acelyrin's score of 1.11 indicating that Innate Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Acelyrin 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IPHA or SLRN? Innate Pharma currently has a consensus target price of $11.50, suggesting a potential upside of 687.67%. Acelyrin has a consensus target price of $11.40, suggesting a potential upside of 166.98%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Innate Pharma is more favorable than Acelyrin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Acelyrin 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has higher earnings and valuation, IPHA or SLRN? Innate Pharma has higher revenue and earnings than Acelyrin. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$66.71M1.77-$8.19MN/AN/AAcelyrinN/AN/A-$381.64M-$2.46-1.74 Is IPHA or SLRN more profitable? Innate Pharma's return on equity of 0.00% beat Acelyrin's return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Acelyrin N/A -44.12%-39.02% SummaryInnate Pharma beats Acelyrin on 10 of the 15 factors compared between the two stocks. Ad Porter & CompanyElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$118.22M$3.09B$5.20B$8.97BDividend YieldN/A1.84%5.23%4.04%P/E RatioN/A15.2685.7113.39Price / Sales1.77315.091,469.4286.49Price / CashN/A175.8435.2935.09Price / Book2.124.044.914.96Net Income-$8.19M-$41.68M$117.36M$224.10M7 Day Performance-2.67%6.57%2.75%2.01%1 Month Performance-22.13%5.81%1.71%9.79%1 Year Performance-40.16%38.20%36.01%29.97% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma3.2829 of 5 stars$1.51+3.4%$11.50+661.6%-40.2%$122.27M$66.71M0.00220Positive NewsSLRNAcelyrin2.8459 of 5 stars$4.67+2.6%$11.40+144.1%-35.0%$468.54MN/A-1.85135Short Interest ↑Positive NewsKRROKorro Bio3.3647 of 5 stars$49.90-4.1%$142.17+184.9%+9.2%$467.56M$14.07M0.0070Short Interest ↓Positive NewsAQSTAquestive Therapeutics2.0315 of 5 stars$5.09flat$9.80+92.5%+101.3%$464.11M$50.58M-11.31160AKBAAkebia Therapeutics4.0738 of 5 stars$2.12+2.9%$7.50+253.8%+99.1%$462.54M$194.62M-8.96167Short Interest ↓AURAAura Biosciences3.8655 of 5 stars$9.22-1.0%$23.00+149.5%+11.7%$460.55MN/A-5.3850Short Interest ↓News CoverageFHTXFoghorn Therapeutics3.3863 of 5 stars$8.18+2.4%$16.00+95.6%+78.8%$454.75M$25.52M-4.16120Short Interest ↓Positive NewsCGCCanopy Growth1.0326 of 5 stars$3.75-3.1%$3.50-6.7%-38.5%$450.47M$280.50M-0.781,029Short Interest ↑KALVKalVista Pharmaceuticals3.8817 of 5 stars$10.23+1.7%$26.00+154.2%+16.4%$442.14MN/A-2.85150Upcoming EarningsShort Interest ↑GHRSGH Research1.3821 of 5 stars$8.47-5.2%$35.67+321.1%+35.6%$440.68MN/A-11.5210TNGXTango Therapeutics3.4824 of 5 stars$3.79-3.8%$13.14+246.8%-49.9%$407.11M$43.38M-3.2190Positive News Related Companies and Tools Related Companies SLRN Alternatives KRRO Alternatives AQST Alternatives AKBA Alternatives AURA Alternatives FHTX Alternatives CGC Alternatives KALV Alternatives GHRS Alternatives TNGX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IPHA) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
